Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebronucimab PK bridging study in healthy Chinese males
NCT06641388Phase 1Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Nov 2024
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of ebronucimab in hypercholesterolemia and hyperlipidemia (2 arms), sponsored by Akeso, Inc. Primary endpoints: Area under curve at Day 57, Maximum (peak) plasma concentration at Day 57 and 1 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
ebronucimab
03
Conditions
hypercholesterolemiahyperlipidemia
Beyond the preview
Go deeper on NCT06641388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641388.